PAD 134 (Hydrochlorothiazide and moexipril hydrochloride 12.5 mg / 15 mg)

Pill imprint PAD 134 has been identified as Hydrochlorothiazide and moexipril hydrochloride 12.5 mg / 15 mg.

Hydrochlorothiazide/moexipril is used in the treatment of high blood pressure and belongs to the drug class ACE inhibitors with thiazides. There is positive evidence of human fetal risk during pregnancy. Hydrochlorothiazide/moexipril 12.5 mg / 15 mg is not a controlled substance under the Controlled Substance Act (CSA).

Hydrochlorothiazide and moexipril hydrochloride

Imprint:

PAD 134

Strength:

12.5 mg / 15 mg

Color:

White

Shape:

Elliptical / Oval

Availability:

Prescription only

Drug Class:

ACE inhibitors with thiazides

Pregnancy Category:

D - Positive evidence of risk

CSA Schedule:

Not a controlled drug

Manufacturer:

Paddock Laboratories, Inc.

National Drug Code (NDC):

00574-0134

Inactive Ingredients:

lactose
magnesium oxide
crospovidone
magnesium stearate
povidone
silicon dioxide
hypromelloses
titanium dioxide
polyethylene glycol 400
polysorbate 80

More info Print Imprint Search

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2016 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.